Becton Dickinson Other Operating Income or Expenses 2010-2025 | BDX
Becton Dickinson annual/quarterly other operating income or expenses history and growth rate from 2010 to 2025. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
- Becton Dickinson other operating income or expenses for the quarter ending March 31, 2025 were $-45M, a 295.65% decline year-over-year.
- Becton Dickinson other operating income or expenses for the twelve months ending March 31, 2025 were $-0.307B, a 212.45% decline year-over-year.
- Becton Dickinson annual other operating income or expenses for 2024 were $-0.222B, a 205.71% decline from 2023.
- Becton Dickinson annual other operating income or expenses for 2023 were $0.21B, a 667.57% decline from 2022.
- Becton Dickinson annual other operating income or expenses for 2022 were $-0.037B, a 81.77% decline from 2021.
Becton Dickinson Annual Other Operating Income or Expenses
(Millions of US $) |
| 2024 |
$-222 |
| 2023 |
$210 |
| 2022 |
$-37 |
| 2021 |
$-203 |
| 2020 |
$-363 |
| 2019 |
$-654 |
| 2018 |
$0 |
| 2017 |
$-410 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$0 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$0 |
| 2010 |
$0 |
| 2009 |
$0 |
Becton Dickinson Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2025-03-31 |
$-45 |
| 2024-12-31 |
$-28 |
| 2024-09-30 |
$-136 |
| 2024-06-30 |
$-98 |
| 2024-03-31 |
$23 |
| 2023-12-31 |
$-11 |
| 2023-09-30 |
$248 |
| 2023-06-30 |
$13 |
| 2023-03-31 |
$-4 |
| 2022-12-31 |
$-47 |
| 2022-09-30 |
$-30 |
| 2022-06-30 |
$-11 |
| 2022-03-31 |
|
| 2021-12-31 |
$4 |
| 2021-09-30 |
$5 |
| 2021-06-30 |
$88 |
| 2021-03-31 |
$-296 |
| 2020-12-31 |
|
| 2020-09-30 |
$-378 |
| 2020-06-30 |
$15 |
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
$-593 |
| 2019-06-30 |
|
| 2019-03-31 |
$-396 |
| 2018-12-31 |
$335 |
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
$-5 |
| 2017-06-30 |
$-741 |
| 2017-03-31 |
|
| 2016-12-31 |
$336 |
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$50.274B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
